Hamden, Connecticut
United States
39
2024-10-24
The entities that hold a legal rights for patent applications filed by inventor Chen Lieping:
Lieping Chen from Hamden, US has applied for patents for these inventions. The list has both pending applications and granted patents:
COSTIMULATORY B7-H1 IN RENAL CELL CARCINOMA PATIENTS: INDICATOR OF TUMOR AGGRESSIVENESS AND POTENTIAL THERAPEUTIC TARGET
#2 | 2022-07-28METHODS AND COMPOSITIONS FOR TREATING A DISEASE OR DISORDER
#3 | 2022-06-02COMPOSITIONS AND METHODS FOR TREATING AUTOIMMUNE DISEASES AND CANCERS
#4 | 2021-12-09Costimulatory B7-H1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target
#5 | 2021-06-10Novel Immune Checkpoint Inhibitors
#6 | 2020-07-30B7-H5, a costimulatory polypeptide
#7 | 2020-01-02Costimulatory B7-H1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target
#8 | 2019-06-27Improved Therapeutic Index of Anti-Immune Checkpoint Inhibitors Using Combination Therapy Comprising A PHY906 Extract, A Scutellaria baicalensis Georgi (S) Extract or A Compound From Such Extracts
#9 | 2018-11-08COMPOSITIONS AND METHODS FOR TREATING AUTOIMMUNE DISEASES AND CANCERS
#10 | 2018-10-25Genome-scale T cell activity array and methods of use thereof
#11 | 2018-09-06B7-H5, a costimulatory polypeptide
#12 | 2018-07-19B7-H1, A NOVEL IMMUNOREGULATORY MOLECULE
#13 | 2018-06-28COSTIMULATORY B7-H1 IN RENAL CELL CARCINOMA PATIENTS: INDICATOR OF TUMOR AGGRESSIVENESS AND POTENTIAL THERAPEUTIC TARGET
#14 | 2018-04-12COSTIMULATORY B7-H1 IN RENAL CELL CARCINOMA PATIENTS: INDICATOR OF TUMOR AGGRESSIVENESS AND POTENTIAL THERAPEUTIC TARGET
#15 | 2017-07-20B7-H3 AND B7-H4, NOVEL IMMUNOREGULATORY MOLECULES
#16 | 2016-09-15COSTIMULATORY B7-H1 IN RENAL CELL CARCINOMA PATIENTS: INDICATOR OF TUMOR AGGRESSIVENESS AND POTENTIAL THERAPEUTIC TARGET
#17 | 2016-09-08COSTIMULATORY B7-H1 IN RENAL CELL CARCINOMA PATIENTS: INDICATOR OF TUMOR AGGRESSIVENESS AND POTENTIAL THERAPEUTIC TARGET
#18 | 2016-08-25Costimulatory B7-H1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target
#19 | 2016-06-02B7-H1 AND B7-H4 IN CANCER
#20 | 2016-04-07Anti-B7-H5 antibodies and their uses
#21 | 2016-04-07B7-H1, A NOVEL IMMUNOREGULATORY MOLECULE
#22 | 2016-04-07B7-H1, A NOVEL IMMUNOREGULATORY MOLECULE
#23 | 2016-01-28Methods of modulating immune function
#24 | 2016-01-28Anti-H7CR antibodies
#25 | 2016-01-07Methods of Modulating Immune Function
#26 | 2015-11-05Anti-human B7-H4 antibodies and their uses
#27 | 2015-08-20B7-H1, A NOVEL IMMUNOREGULATORY MOLECULE
#28 | 2015-07-23B7-H5, a costimulatory polypeptide
#29 | 2015-02-12COSTIMULATORY B7-H1 IN RENAL CELL CARCINOMA PATIENTS: INDICATOR OF TUMOR AGGRESSIVENESS AND POTENTIAL THERAPEUTIC TARGET
#30 | 2014-11-13B7-H1 AND B7-H4 IN CANCER
#31 | 2014-08-21B7-H3 and B7-H4, novel immunoregulatory molecules
#32 | 2013-12-12B7-H7 ANTIBODIES AND METHOD OF USE
#33 | 2013-11-28B7-H5, a costimulatory polypeptide
#34 | 2013-10-10B7-H3 and B7-H4, novel immunoregulatory molecules
#35 | 2012-09-06Enhancement of immune responses by 4-1 BB-binding agents
#36 | 2012-06-07Methods for treating inflammation using B7-H4 polypeptides and fragments thereof
#37 | 2012-03-15B7-H1 antibodies and method of use
#38 | 2012-01-05Nucleic acid molecules encoding B7-DC variants
#39 | 2011-10-06Antibody specific for B7-H5, a costimulatory polypeptide
478540 ⎘